Our publications keep professionals working across the public, private, and academic sectors informed on the most important developments and issues in health security and biosecurity.
Find an article or report by keywords:
As of February 2021, 3 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern with worrisome characteristics have emerged, each on a different continent. The B.1.1.7 variant, first identified in the United Kingdom, is substantially more transmissible than previously circulating variants. The B.1.351 and P.1 variants, first identified in South Africa and Brazil, respectively, both exhibit some degree of immune escape. Each of these variants has precipitated resurgences in the communities where they have become dominant. All 3 have already been identified at low levels in the United States. If they gain a foothold, the same resurgences can be expected here.
Funding for increased genomic surveillance is expected in the next Congressional supplemental, among several investments in SARS-CoV-2 research. Key efforts to expand capacity and improve surveillance systems should be funded with this money. New guidance and policies are also needed to maximize the response. Notably, investments made now to build genomic surveillance infrastructure for coronavirus disease 2019 (COVID-19) will not only help us respond to the pandemic now but will also improve response for outbreaks of other pathogens in the future.
This document explains the current status of SARS-CoV-2 surveillance, sequencing, and variant characterization and provides recommendations for increasing the United States’ capacity to respond to new variants.